1 results match your criteria: "UK hCentre Leon Berard[Affiliation]"
Trabectedin in advanced synovial sarcomas: a multicenter retrospective study from four European institutions and the Italian Rare Cancer Network.
Anticancer Drugs
July 2015
aAdult Mesenchymal Tumor Medical Oncology Unit, Department of Cancer Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milan bDepartment of Oncology, General Hospital of Agrigento, Agrigento cDepartment of Oncology, Ospedale Civile SS Annunziata Sassari, Sassari dMedical Oncology Unit, University Hospital S. Chiara, Pisa eDepartment of Anatomic Pathology, General Hospital of Treviso, Treviso, Italy fDepartment of Oncology, University College of London Hospital gSarcoma Unit, Royal Marsden, London, UK hCentre Leon Berard, Lyon iInstitut Gustave Roussy, Villejuif, France.
Treatment options for patients with metastatic synovial sarcoma are limited. Over recent years, trabectedin has emerged as an effective agent for patients with advanced soft tissue sarcomas resistant to anthracyclines and ifosfamide. The aim of this retrospective analysis was to study the efficacy of trabectedin in the subgroup of synovial sarcomas.
View Article and Find Full Text PDF